Introduction
============

Glaucomatous optic neuropathy is a leading cause of irreversible vision loss and blindness in the world. Primary open-angle glaucoma (POAG) is one of the most prevalent forms of glaucoma, and several of the risk factors involved in POAG include family history, elevated intraocular pressure (IOP), age, race, and responsiveness to glucocorticoids (GCs). Heredity is a major risk factor in POAG \[[@r1]\], and several glaucoma loci have been mapped and several genes identified \[[@r2],[@r3]\]. Elevated IOP, which is due to a compromised aqueous humor outflow facility at the trabecular meshwork (TM), is the primary risk factor associated with the development and progression of glaucoma \[[@r4],[@r5]\].

The therapeutic use of GCs can lead to the development of ocular hypertension and iatrogenic open-angle glaucoma in susceptible individuals. This secondary glaucoma clinically mimics many features of POAG. Although only approximately 30%--40% of the normal population are "steroid responders" (i.e., develop glucocorticoid-induced ocular hypertension), most of POAG patients are steroid responders. Normal individuals who are steroid responders are at higher risk for subsequently developing POAG \[[@r6],[@r7]\], and steroid responsiveness appears to also be heritable \[[@r8]-[@r10]\]. In addition, there have been reports suggesting that endogenous cortisol may play a role in the pathogenesis of POAG \[[@r11]-[@r13]\].

There are multiple isoforms of the glucocorticoid receptor (GR) \[[@r14]\]. GRα is the ligand binding form of the receptor that is responsible for the physiologic and pharmacological effects of GCs. GRβ is an alternatively spliced form of the receptor, which lacks the conventional ligand binding domain, does not bind GCs, and acts as a dominant negative regulator of GC activity \[[@r15],[@r16]\]. Increased expression of GRβ has been implicated in the development of several steroid resistant diseases \[[@r17],[@r18]\]. More germane to glaucoma, recent work in our laboratory has shown that glaucomatous TM cells have lower levels of GRβ compared to normal TM cells, and this appears to be responsible for increased GC sensitivity in the glaucomatous TM cells \[[@r19]\]. Levels and activities of these GR isoforms are regulated by alternative splicing as well as by nuclear translocation of the receptors. A variety of proteins and RNAs are involved in alternative splicing of gene transcripts \[[@r20]\], and the splicesome proteins SFRS9 \[[@r21]\] and SFRS5 \[[@r22]\] are involved in alternative splicing of the GR. In addition, the immunophilins FKBP4 and FKBP5, along with other factors such as Hsp90, are responsible for the nuclear translocation of GRα and GRβ, respectively \[[@r23]\].

The purpose of the present study was to determine whether common polymorphisms in several of the genes responsible for GC activity are involved in steroid responsiveness and/or POAG. Single nucleotide polymorphism (SNP) genotyping has been successfully used to identify several risk alleles and disease associated genes \[[@r24]-[@r26]\], so we have used this technology to evaluate potential involvement of common alleles in genes for the glucocorticoid receptor (*NR3C1*), immunophilins (*FKBP4* and *FKBP5*), and SR splicesome proteins (*SFRS3*, *SFRS5*, *SFRS9*) in the development of GC-induced ocular hypertension and POAG.

Methods
=======

The study was approved by the University of Iowa's Institutional Review board and informed consent was obtained from study participants. The study included a cohort of 107 subjects that have a history of steroid-induced ocular hypertension, 197 subjects with POAG, and 400 normal control subjects that were all recruited from the Ophthalmology Clinics at the University of Iowa (Iowa City, IA). The majority of patients were Caucasian with approximately equal numbers of males and females in each group.

The cohort of glaucoma patients underwent complete ophthalmologic evaluation including slit lamp examination, Goldmann applanation tonometry, gonioscopy, perimetry, dilated stereoscopic examination of the optic nerve heads, and optic nerve head photography. Visual fields were assessed using the SITA 24--2 program on the Humphrey Field Analyzer (Humphrey-Zeiss, Dublin, CA). Patients who were unable to reliably perform automated perimetry were tested with Goldmann manual kinetic perimetry (Haag-Streit Instruments, Koeniz, Switzerland) using the Armaly-Drance protocol.

Patients were considered to have primary open angle glaucoma regardless of IOP if they had open iridocorneal angles, and evidence of glaucomatous optic nerve damage in at least one eye. Those with evidence of a secondary etiology of glaucoma such as pigment dispersion, pseudoexfoliation, inflammation, or a history of glucocorticoid therapy were excluded. Glaucomatous optic nerve damage was based on both optic nerve and visual field examination. Glaucomatous optic nerves had cup-to-disc ratios of greater than 0.7 with thinning of the neural rim, asymmetry of the optic nerve cup-to-disc ratio of \>0.2, or photographic documentation of progressive loss of the neural rim. Patients were required to have visual fields of adequate quality for interpretation. For Humphrey visual fields this required a false positive rate, false negative rate and fixation loss rate of less than 33% \[[@r27]\]. Humphrey visual field evidence of glaucoma was based on the Collaborative Normal Tension Glaucoma Treatment Trial criteria \[[@r28]\]. Patients evaluated using manual kinetic perimetry were required to exhibit depression of the visual field in an arcuate pattern respecting the nasal horizontal meridian.

Corticosteroid responders included patients who exhibited an elevation of IOP of more than 5 mmHg after administration of glucocorticoid steroids (prednisolone acetate, dexamethasone, prednisolone phosphate, fluorometholone, betamethasone, or oral prednisone) for at least 4 weeks or who exhibited glaucomatous optic nerve damage (as defined above) after a prolonged course of oral or topical glucocorticoids.

The normal controls were obtained from the Comprehensive Ophthalmology Clinic at the University of Iowa. These subjects were all over age 59 and had no history of glaucoma and no family history of glaucoma. They had a normal slit lamp and optic nerve head examination. They were not tested for steroid responsiveness.

A total of 48 SNPs were selected using [HapMap](http://www.hapmap.org/) data to maximize the power to detect an association using the UCLA [Association Study Design Server](http://design.cs.ucla.edu/) online software package. Tag SNPs were selected using [HapMap](http://www.hapmap.org/) data to maximize the statistical power with this software as previously described \[[@r29]\]. The cohorts were genotyped at 4 SNPs within *SFRS3*, 5 SNPs within *SFRS5*, 5 SNPs within *SFRS9*, 3 SNPs within *FKBP4*, 10 SNPs within *FKBP5*, and 21 SNPs within *NR3C1* using a mass spectroscopy-based system (Sequenom, San Diego, CA). Genotyping was conducted using theMassArray platform and iPlex Gold reagents with the manufacturer's protocol by GeneSeek (Lincoln, NE). SNP allele frequencies were compared between subjects and controls using Fisher's exact test. Genotype frequencies were compared using χ^2^ analysis. For rare variants for which the χ^2^ test was unsuitable, we used Fisher's exact test. P-values were calculated using [R](http://www.r-project.org) 2.10.1. The Bonferroni correction was used to adjust p-values for multiple measures as needed.

Power for the current study was estimated by simulation for different values of minor allele frequency and disease odds ratio (OR) for having an additional copy of a disease allele. Simulated data were fitted using a logistic regression in which the explanatory variable is genotype coded as 0, 1, or 2. The power is computed as the proportion the slope estimate is significantly different from 0 at level 0.05 out of 10,000 simulation replicates.

Results
=======

A cohort of 107 subjects with a history of steroid-induced ocular hypertension (steroid-responders), 197 POAG patients, and 400 control subjects from Iowa were genotyped at a total of 48 SNPS in *SFRS3*, *SFRS5*, *SFRS9*, *FKBP4*, *FKBP5*, and *NR3C1*. Given the size of our cohort, we have adequate power under most conditions to detect powerful risk factors for the steroid response or POAG that have an odds ratio of greater than 1.75. High call rates (mean 99%) were obtained at these SNPs, which have an average spacing of 7.1 kb. Comparisons of allele frequencies and genotype frequencies of these SNPs were made between the steroid-responders and control subjects and also between POAG patients and normal subjects ([Table 1](#t1){ref-type="table"}). There was no significant difference in the allele frequencies or genotypes of SNPs in *SFRS5, SFRS9, FKBP5,* and *NR3C1* between patients and the control subjects (p\>0.05 uncorrected for multiple measures).

###### SNP genotyping results.

  ** **     ** **                                                                   ** **       ** **   ** **     **p-values (allele frequency)**   **p-values (genotype frequency)**               
  --------- ----------------------------------------------------------------------- ----------- ------- --------- --------------------------------- ----------------------------------- ----------- -----------
  *SFRS3*   [rs7759778](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7759778)     36660245    10174   0.25      0.084                             0.77                                **0.046**   0.10
            [rs1406945](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1406945)     36670419    7925    0.283     **0.027**                         **0.043**                           **0.033**   **0.036**
            [rs7344](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7344)           36678344    10783   0.217     0.11                              0.11                                **0.011**   0.073
            [rs13202984](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=13202984)   36689127            0.292     0.15                              0.27                                0.33        0.44
  *SFRS5*   [rs7153985](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7153985)     69296240    9254    0.117     0.13                              0.59                                0.36        0.17
            [rs3104](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3104)           69305494    4185    0.317     0.86                              0.83                                0.84        0.94
            [rs8019166](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=8019166)     69309679    3579    0.195     0.34                              0.86                                0.26        0.74
            [rs4646296](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=4646296)     69313258    4853    0.059     0.46                              0.71                                0.38        0.87
            [rs17556915](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=17556915)   69318111            0.175     0.30                              0.41                                0.37        0.64
  *SFRS9*   [rs2235222](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2235222)     119376576   3096    0.13333   0.37                              0.94                                0.53        0.60
            [rs3847971](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3847971)     119379672   4985    0.35833   0.63                              0.48                                0.74        0.76
            [rs9040](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=9040)           119384657   992     0.3       0.56                              0.32                                0.39        0.58
            [rs7027](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7027)           119385649   10520   0.15      0.27                              0.14                                0.68        0.37
            [rs540520](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=540520)       119396169           0.28333   0.30                              0.34                                0.36        0.54
  *FKBP4*   [rs2968909](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2968909)     2768125     3706    0.15833   **0.013**                         0.24                                0.40        0.47
            [rs3759411](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3759411)     2771831     6156    0.1       0.051                             0.51                                0.87        0.67
            [rs1981655](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1981655)     2777987             0.05833   0.22                              0.73                                0.18        0.72
  *FKBP5*   [rs755658](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=755658)       35657648    12970   0.05833   0.17                              0.83                                0.35        0.92
            [rs3798346](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3798346)     35670618    334     0.325     0.40                              0.55                                0.66        0.60
            [rs9366890](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=9366890)     35670952    4108    0.175     0.92                              0.87                                0.96        0.97
            [rs9296158](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=9296158)     35675060    2199    0.24167   0.56                              0.55                                0.56        0.59
            [rs4713899](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=4713899)     35677259    6206    0.15      0.92                              \>0.99                              0.74        0.55
            [rs737054](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=737054)       35683465    3515    0.225     0.26                              0.68                                0.24        0.26
            [rs3777747](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=3777747)     35686980    10068   0.43333   0.54                              0.90                                0.41        0.74
            [rs9380524](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=9380524)     35697048    28515   0.14167   0.23                              0.24                                0.46        0.46
            [rs6912833](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=6912833)     35725563    4336    0.24167   0.88                              0.46                                0.18        0.67
            [rs17614642](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=17614642)   35729899            0.13333   \>0.99                            \>0.99                              0.64        0.81
  *NR3C1*   [rs174048](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=174048)       142630597   4611    0.18333   0.30                              0.19                                0.40        0.26
            [rs17287745](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=17287745)   142635208   2006    0.39167   0.43                              0.90                                0.67        0.57
            [rs17287758](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=17287758)   142637214   12202   0.15833   0.91                              0.79                                0.44        0.45
            [rs17209251](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=17209251)   142649416   1085    0.20833   0.52                              0.77                                0.75        0.88
            [rs10482672](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=10482672)   142672726   4762    0.14167   0.59                              0.60                                0.51        0.62
            [rs33388](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=33388)         142677488   26078   0.45833   0.76                              0.42                                0.68        0.39
            [rs2918418](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2918418)     142703566   7003    0.175     0.41                              0.15                                0.64        0.37
            [rs4912905](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=4912905)     142710569   25628   0.23333   0.93                              0.15                                0.41        0.27
            [rs2963155](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2963155)     142736197   11736   0.3       0.11                              0.34                                0.19        0.13
            [rs9324921](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=9324921)     142747933   13827   0.05833   0.72                              0.35                                0.88        0.39
            [rs10482616](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=10482616)   142761760   10917   0.125     0.67                              0.54                                0.53        0.57
            [rs9324924](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=9324924)     142772677   166     0.31667   0.52                              0.11                                0.75        0.18
            [rs7701443](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7701443)     142772843   2075    0.29167   0.94                              0.24                                0.98        0.45
            [rs4244032](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=4244032)     142774918   1807    0.21667   0.70                              0.44                                0.76        0.51
            [rs4607376](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=4607376)     142776725   4948    0.45      0.19                              \>0.99                              0.30        0.73
            [rs13182800](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=13182800)   142781673   4422    0.16667   0.70                              0.76                                0.80        0.79
            [rs12054797](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=12054797)   142786095   1130    0.24167   0.45                              0.090                               0.74        0.31
            [rs12656106](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=12656106)   142787225   1915    0.3       0.62                              0.15                                0.85        0.25
            [rs12656106](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=12656106)   142789140   8660    0.4833    0.82                              0.67                                0.96        0.89
            [rs12521436](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=12521436)   142797800   699     0.175     0.36                              \>0.99                              0.29        0.97
            [rs4912913](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=4912913)     142798499           0.4833    0.94                              \>0.99                              0.37        0.31

When the genotype frequencies of four SNPs in *SFRS3* were compared between steroid-responders and control subjects, 3 contiguous SNPs ([rs7759778](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7759778), [rs1406945](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1406945), and [rs7344](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7344)) produced p-values \<0.05 (uncorrected for multiple measures). Similarly, an uncorrected p-value of 0.036 was produced when the genotypes were compared between POAG patients and control subjects at one of these *SFRS3* SNPs ([rs1406945](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1406945)). Comparison of allele frequencies at [rs1406945](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1406945) also produced uncorrected p-values \<0.05. Finally, comparison of the allele frequencies of a single SNP in *FKBP4* ([rs2968909](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2968909)) between steroid responders and control subjects produced a p-value of 0.013. The allele and genotype frequencies of these SNPs are shown in [Table 2](#t2){ref-type="table"}. However, when adjusted for multiple measures with a Bonferroni correction, none of these p-values is statistically significant.

###### Genotype and allele frequencies of informative SNPs.

  **rs7759778**                                                  
  --------------- ------ ------ ----- --- -------- ------ ------ -----
  Genotype        Norm   POAG   SR        Allele   Norm   POAG   SR
  C               237    121    58        C        613    300    152
  CG              139    58     36        G        177    90     60
  G               19     16     12        Total    790    390    212
  (blank)         5      2      1                                 
  Grand Total     400    197    107                               
  **rs1406945**                                                  
  Genotype        Norm   POAG   SR        Allele   Norm   POAG   SR
  C               200    88     45        C        568    261    138
  GC              168    85     48        G        216    131    76
  G               24     23     14        Total    784    392    214
  (blank)         8      1      0                                 
  Grand Total     400    197    107                               
  **rs7344**                                                     
  Genotype        Norm   POAG   SR        Allele   Norm   POAG   SR
  C               12     14     11        C        156    93     53
  TC              132    65     31        T        638    299    161
  T               253    117    65        Total    794    392    214
  (blank)         3      1      0                                 
  Grand Total     400    197    107                               

Discussion
==========

Glucocorticoid administration can elevate IOP in susceptible individuals that can lead to the development of an iatrogenic secondary open-angle glaucoma that mimics POAG \[[@r30]\]. Only a subset of normal individuals have the propensity to develop steroid-induced ocular hypertension. In contrast, most POAG patients are steroid responders, and POAG patients have also been reported to have greater sensitivity to cutaneous GC vasoconstriction \[[@r31]\]. However, the exact molecular mechanism(s) responsible for steroid responsiveness is currently unclear.

One potential explanation for altered GC sensitivity is inter-individual differences in the expression levels of GRβ, the dominant negative isoform of the GR. There have been numerous reports of the potential involvement of GRβ in GC resistant diseases such as inflammatory bowel syndrome, rheumatoid arthritis, and asthma, among others \[[@r17],[@r18]\]. We have shown that TM cells derived from glaucomatous donors have lower levels of GRβ compared to normal TM cells and that GRβ levels regulate TM responses to dexamethasone, such as induction of myocilin, fibronectin, and GRE-luciferase as well as inhibition of TM cell phagocytosis \[[@r19],[@r32]\]. Alternative splicing of GR is regulated by specific SR splicesome proteins \[[@r21],[@r22]\]. In addition, translocation of both GRα and GRβ to the nucleus is essential for the biologic activities of these receptor isoforms, and immunophilins FKBP5 and FKBP4, along with other cofactors, are co-chaperones for this GRβ and GRα translocation \[[@r23]\].

Despite evidence implicating the involvement of GRβ in the steroid responsiveness and POAG, it does not appear that major heritable risk alleles in genes encoding GR, GR splicesome proteins, or GR nuclear translocation proteins are involved in the development of these conditions. Although there was a suggestion that genotypes and allele frequencies of *SFRS3* SNPs may be different in steroid responders and POAG patients compared to ethnically-matched controls, these allele frequencies were not statistically significant different when corrected for multiple measures. These data suggest that ancestral mutations in *SFRS3*, *SFRS5*, *SFRS9*, *FKBP4*, *FKBP5*, and *NR3C1* are not strong risk factors for disease. Our study was adequately powered to identify strong risk factors for the steroid response or POAG (odds ratio \>1.75). However, the suggestive p-values obtained in our studies of *SFRS3* might be further pursued with a larger focused association study with power to detect variations that confer modest risk for steroid responsiveness or POAG. Also, it remains possible that non-ancestral variations in these genes (that cannot be detected by association studies) may confer risk for steroid responsiveness or POAG.

Another recent study examined GR polymorphisms in patients who had received intravitreal triamcinolone injections \[[@r33]\]. There were no statistically significant associations between any of the 6 tested GR polymorphisms and the magnitude of IOP elevation in these patients. However, only 52 patients were evaluated in this study, some of whom were steroid responsive and others non-responsive (although the number of responders was not disclosed), so only a very strong risk correlation would have been identified. In our study, we examined a larger number of characterized steroid responders with 21 SNPs spanning the *GR* gene, and we also did not find an association. However, these two studies differ in several ways. In our study, we had more steroid responders (n=107), but we did not have access to significant numbers of clinically characterized nonresponders. We therefore had to compare the steroid responder population with the normal control population, a significant minority of which are most likely untested steroid responders (approximately 30%), which makes it more difficult to see a correlation between these two groups.

Currently, the propensity to develop GC-induced ocular hypertension must be determined empirically. Therefore, all patients on protracted GC therapy should have their IOPs monitored periodically throughout the course of GC therapy. In addition, patients who are documented steroid responders have a higher risk for developing POAG. Therefore, there is a definite need for a reliable test that would predict steroid responsiveness in patients. Unfortunately, it does not appear that genetically screening for the SNPs in the genes evaluated in our study will be useful markers to predict steroid-induced ocular hypertension or POAG, at least in the current population studied.
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